Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Accumulated Expenses: 2019-2024

Historic Accumulated Expenses for Allogene Therapeutics (ALLO) over the last 6 years, with Dec 2024 value amounting to $30.1 million.

  • Allogene Therapeutics' Accumulated Expenses rose 3.95% to $28.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.1 million, marking a year-over-year increase of 3.95%. This contributed to the annual value of $30.1 million for FY2024, which is 3.38% down from last year.
  • Per Allogene Therapeutics' latest filing, its Accumulated Expenses stood at $30.1 million for FY2024, which was down 3.38% from $31.2 million recorded in FY2023.
  • In the past 5 years, Allogene Therapeutics' Accumulated Expenses ranged from a high of $44.9 million in FY2020 and a low of $30.1 million during FY2024.
  • Over the past 3 years, Allogene Therapeutics' median Accumulated Expenses value was $31.2 million (recorded in 2023), while the average stood at $33.7 million.
  • Per our database at Business Quant, Allogene Therapeutics' Accumulated Expenses spiked by 88.59% in 2020 and then decreased by 21.54% in 2023.
  • Allogene Therapeutics' Accumulated Expenses (Yearly) stood at $44.9 million in 2020, then dropped by 16.56% to $37.5 million in 2021, then increased by 5.99% to $39.7 million in 2022, then dropped by 21.54% to $31.2 million in 2023, then fell by 3.38% to $30.1 million in 2024.